METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA
Clinical trials for METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack shows promise for rare bladder and kidney cancers
Disease control Recruiting nowThis study tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in people with rare genitourinary cancers that have spread. The goal is to see if this mix can shrink tumors or stop them from growing. About 314 adults with these rare cancers will take part. T…
Matched conditions: METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:38 UTC
-
Radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a radioactive drug called lutetium Lu 177 dotatate in 30 people with prostate cancer that has spread and has neuroendocrine features. The drug targets and kills cancer cells that have a specific protein on their surface. The goal is to see if it can shrink tumors…
Matched conditions: METASTATIC PROSTATE SMALL CELL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:41 UTC